BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
more
information on access to our products, please call our
customer service line at 1-800-469-0261.
Stay up to date on the latest news and innovations from BDSI.
Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential
Read moreRALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial
Read moreRALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of
Read moreThere are no events to display
Stay up to date on the latest news
Get started now